Hypothyroidism is common, and in iodine-sufficient areas, it is primarily caused by autoimmune destruction of the thyroid gland. Observational studies have consistently shown an inverse association between serum 25-hydroxyvitamin D concentration and autoimmune diseases; however, there is a lack of evidence from randomized controlled trials to support a benefit of vitamin D supplementation, particularly for autoimmune thyroid diseases. We, therefore, aimed to assess the effect of vitamin D supplementation on the incidence of hypothyroidism. We analyzed data from the D-Health Trial ( = 21,315), a randomized double-blind placebo-controlled trial of 60,000 international units per month of supplemental vitamin D among Australians aged 60 years and over. Hypothyroidism, a tertiary outcome of the D-Health Trial, was defined by treatment with levothyroxine, ascertained through linkage with the Australian Pharmaceutical Benefits Scheme. The outcome was time to first prescription of levothyroxine. We began follow-up at 12 months after randomization; people who had died or who had been dispensed levothyroxine during the first year were excluded. Flexible parametric survival models were used to assess the effect of vitamin D supplementation on hypothyroidism, overall and within strata defined by age, sex, body mass index, and predicted baseline vitamin D status. We included 17,851 participants in the main analysis (vitamin = 8939; placebo = 8912). During a median follow-up of 4.1 years (interquartile range 4.1-4.1), 293 participants developed hypothyroidism (vitamin = 138 [1.5%]; placebo = 155 [1.7%]). Vitamin D supplementation did not significantly reduce the incidence of hypothyroidism (overall hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.71-1.12). There was some suggestion of an effect in females (overall HR 0.78; CI 0.58-1.06) but not in males (overall HR 1.06; CI 0.74-1.50; interaction 0.20). Vitamin D supplementation did not reduce the incidence of hypothyroidism overall; however, the possible beneficial effect observed in females warrants further investigation. Australian New Zealand Clinical Trials Registry: ACTRN12613000743763.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/thy.2023.0317 | DOI Listing |
Adv Clin Exp Med
January 2025
specialist, Oral and Maxillofacial Surgery, Guwahati, India.
Background: Vitamin D supplementation could offer irritable bowel syndrome (IBS) patients significant improvements in terms of symptom severity and overall quality of life (QoL). Yet, the potential benefits and risks associated with vitamin D supplementation still require additional investigation.
Objectives: We aimed to evaluate the impact of vitamin D supplementation on IBS using a systematic review and meta-analysis.
Indian J Pediatr
January 2025
Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Vet Sci
December 2024
Gastrovet, São Paulo 04077003, Brazil.
Gallbladder mucocele, cholelithiasis, choledocholithiasis, and cholecystitis are significant contributors to morbidity and mortality in dogs. The exact etiology of these conditions remains poorly understood, though various factors, such as endocrinopathies, dyslipidemia, and impaired gallbladder motility, have been suggested as potential contributors. Surgical intervention has been described as the first choice of treatment when biliary rupture or obstruction is suspected; however, medical management may be an important part of therapeutic or preventative strategy.
View Article and Find Full Text PDFDiscov Med
January 2025
Faculty of Medicine, Institute of Anatomy, University of Belgrade, 11000 Belgrade, Serbia.
Two billion people worldwide suffer from anemia, which can lead to the onset of cardiac disorders; nevertheless, the precise mechanisms remain unclear. There are at least three distinct mechanisms by which iron deficiency (ID) contributes to the development of cardiac disorders. First, ID increases concentrations of intact fibroblast growth factor-23 (iFGF-23), which promotes left ventricular hypertrophy.
View Article and Find Full Text PDFAm J Prev Cardiol
December 2024
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Objectives: In observational studies, older adults with low serum vitamin D levels are at higher risk of cardiovascular disease (CVD), but randomized trials have failed to demonstrate reduction in CVD risk from vitamin D supplementation, possibly because the doses of vitamin D supplements tested were too low. Our objective was to determine if higher doses of vitamin D supplementation reduce high-sensitivity cardiac troponin (hs-cTnI) and N-terminal pro-b-type natriuretic peptide (NT-proBNP), markers of subclinical CVD.
Methods: The Study to Understand Fall Reduction and Vitamin D in You (STURDY) was a double-blind, randomized, response-adaptive trial that tested the effects of 4 doses of vitamin D3 supplementation (200, 1000, 2000, 4000 IU/day) on fall risk among older adults with low serum 25-hydroxyvitamin D concentrations (10-29 ng/mL).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!